Low-dose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels

Archives of Internal Medicine

Volumn 157, Issue 22, 1997, Pages 2609-2615

  Genant, Harry K ^a   Lucas, Johna ^b   Weiss, Stuart ^c   Akin, Mark ^d   Emkey, Ronald ^e   McNaney Flint, Heidi ^f   Downs, Robert ^g   Mortola, Joseph ^h   Watts, Nelson ⁱ   Yang, Hwa Ming ^j   Banav, Niranyan ^j   Brennan, John J ^j   Nolan, Joseph C ^j  

^a Univ of California Sch of Medicine   (United States)

^b DEPARTMENT OF COLORECTAL SURGERY   (United States)

^c S Diego Endocr and Medical Clinic   (United States)

^d Pharmaco   (United States)

^e Bone Research Center   (United States)

^f Physicians to Women   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ EMORY UNIVERSITY   (United States)

^j Solvay Pharmaceuticals Inc   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; ENDOMETRIUM HYPERPLASIA; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 9844237579     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.22.2609     Document Type: Article

References (48)

1. Riggs BL, Melton LJ. Involutional osteoporosis. N Engle J Med. 1986;314:1676-1686.
2. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 1985;7:178-208.
3. Melton LJ III, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989;129:1000-1011.
4. Recker RR, Saville PD, Heaney RP. Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med. 1977;87:649-655.
5. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy 1: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol. 1979;53:277-281.
6. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 1980;303:1195-1198.
7. Horsman A, Jones M, Francis R, Nordin C. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med. 1983;309:1405-1407
8. Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund KE, Transbøl I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin invest 1980;10:273-279.
9. Harris ST, Genant HK, Baylink DJ, et al. The effects of estrone (Ogen) on spinal bone density of postmenopausal women. Arch Intern Med. 1991;151:1980-1984.
10. Genant HK, Baylink DJ, Gallagher JC, Harris ST, Steiger P, Herber M. Effect of estrone sulfate on postmenopausal bone loss. Obstet Gynecol. 1990;76:579-584.
11. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol. 1984;63:759-763.
12. Genant HK, Cann CE, Ettinger B, Gordon GS. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med. 1982;97:699-705.
13. Genant HK, Baylink DJ, Gallagher JC. Estrogens in the prevention of osteoporosis in postmenopausal women. Am J Obstet Gynecol. 1989;161:1842-1846.
14. Lindsay R. Prevention of postmenopausal osteoporosis. Obstet Gynecol Clin North Am. 1987;14:63-76.
15. Ettinger B. Prevention of osteoporosis: treatment of estradiol deficiency. Obstet Gynecol. 1988;72(5 suppl):12S-17S.
16. Lindsay R. Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med. 1993;95(suppl 5A):37S-39S.
17. Lindsay R. Estrogens, bone mass, and osteoporotic fractures. Am J Med. 1991;91(suppl 5B):10S-13S.
18. Christiansen C. Prevention and treatment of osteoporosis with hormone replacement therapy. Int J Fertil. 1993;38(suppl 1);45-54.
19. Ettinger B. Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis. Clin Ther. 1993;15:950-962.
20. Selby PL, Peacock M. Dose-dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women. BMJ. 1986;293:1337-1339.
21. Reginster JL, Sarlet N, Deroisy R, Albert A, Gaspard U, Franchimont P. Minimal serum levels of serum estradiol prevent postmenopausal bone loss. Calcif Tissue Int. 1992;51:340-343.
22. Whitehead MI, King RJB, McQueen J, Campbell S. Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/ progestogen therapy. J R Soc Med. 1979;72:322-327.
23. Schiff I, Sela HK, Cramer D, Tulchinsky D, Ryan KJ, Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril. 1982;37:79-82.
24. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol. 1994;170(5 pt 1):1213-1223.
25. Weiss NS, Szekely DR, English DR, Schweid AL. Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA. 1979;242:261-264.
26. Hulka BS, Fowler WC Jr, Kaufman DG, Grimson RC, Greenberg BG, Hogue CJ. Estrogen and endometrial cancer: cases and two control groups from North Carolina. Am J Obstet Gynecol. 1980;137:92-101.
27. Buring JE, Bain CJ, Ehrmann RL. Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol. 1986;124:434-441.
28. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304-313.
29. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study). JAMA. 1996;276:1397-1403.
30. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-1593.
31. Hulka BS. Links between hormone replacement therapy and neoplasia. Fertil Steril. 1994;62(suppl 2):168S-175S.
32. Gorsky RD, Koplan JP, Peterson HB, Thacker SB. Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis. Obstet Gynecol. 1994;83; 161-166.
33. Cauley JA, Lucas LL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women. JAMA. 1996;276:1404-1408.
34. Archer DF, McIntyre-Seltman K, Wilborn WW, et al. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol. 1991;165:317-322.
35. Trabal JF, Lenihan JP, Melchione TE, et al. Low-dose unopposed estrogens: preliminary findings on the frequency and duration of vaginal bleeding in postmenopausal women receiving esterified estrogens over a two-year period. Menopause. In press.
36. Notelovitz M, Varner RE, Rebar RW, et al. Minimal endometrial proliferation over a two-year period in postmenopausal women taking 0.3 mg of unopposed esterified estrogens. Menopause. 1997;4:80-88.
37. Bauer DC, Cauley JA, Ensrud KE, Nevitt MC, Stone K, Cummings SR. Women with low serum estradiol have an increased risk of vertebral fracture. Osteoporos Int. 1996;6(suppl 1):92.
38. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med. 1987;106:40-45.
39. MacLennan AH, MacLennan A, Wenzel S, Chambers HM, Eckert K. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med J Aust. 1993;159:102-106.
40. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med. 1991;90:171-178.
41. Webber CE, Blake JM, Chambers LF, Roberts JG. Effects of 2 years of hormone replacement upon bone mass, serum lipids and lipoproteins. Maturitas. 1994;19:13-23.
42. Troy SM, Hicks DR, Parker VR, Jusko WJ, Rofsky HE, Porter RJ. Differences in pharmacokinetics and comparative bioavailability between Premarin and Estratab in healthy postmenopausal women. Curr Ther Res. 1994;55:359-372.
43. Hazzard WR. Estrogen replacement and cardiovascular disease: serum lipids and blood pressure effects. Am J Obstet Gynecol. 1989;161:1847-1853.
44. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273:199-208.
45. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
46. Gelfand MM, Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol. 1989;74(3 pt 1):398-402.
47. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol. 1994;83(5 pt 1):686-692.
48. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA. 1996;275:370-375.